6 Best Peptides for Bloating

What to Know Before Choosing a Peptide for Bloating

Bloating is a symptom, not a single condition, and the compounds people reach for reflect that complexity. Some work by repairing the intestinal lining. Some target gut inflammation directly. One delivers butyrate, the primary fuel for colon cells, to support a healthier microbiome and tighter gut barrier. A compound earns a place on this list because people use it or are actively discussing using it for bloating. FDA-approved status, available clinical trial data, and regulatory classification are not filters here. What matters is whether real people are turning to a compound for this goal. Evidence strength is stated honestly inside each entry, because it varies enormously across this field.

None of these compounds is FDA-approved specifically for bloating. Some are research peptides accessed through telemedicine or peptide therapy clinics. One is an investigational drug with completed human trials. Two are dietary supplements available without a prescription. The regulatory and evidence landscape is genuinely mixed, and this guide reflects that honestly rather than quietly narrowing the list to the easiest compounds to defend.

The entries are numbered by how prominently each compound appears in research and real-world use for bloating, not as a recommendation of one over another. The right choice depends on factors this article cannot know: the root cause of your bloating, your existing health conditions, and what you are already using. That personalized layer belongs with a good clinician or a tool built for exactly that job.

1. BPC-157: For Gut Lining Repair and Mucosal Healing

BPC-157, short for Body Protection Compound-157, is a synthetic peptide derived from a partial sequence found in human gastric juice, which is part of why it keeps showing up in gut-health conversations. It has no FDA approval and is classified as a research compound, yet it is by far the most widely discussed peptide for chronic bloating and gut healing across integrative medicine, biohacker communities, and forums dedicated to IBS and leaky gut.

People use it for bloating primarily because of how it acts on the gut lining. BPC-157 promotes angiogenesis, the formation of new blood vessels, by upregulating VEGF and FGF, two growth factors that function like a construction dispatch signal telling the body to route materials toward damaged tissue. More blood vessel growth at the site of gut damage means faster delivery of what is needed for mucosal repair. It also reduces gut inflammation indirectly by interfering with NF-kB, the signaling protein that acts as a master switch for inflammatory responses in the body, and by lowering pro-inflammatory proteins including TNF-alpha and IL-6.

The human evidence is thin, and saying so clearly matters. A 2025 systematic review found only one retrospective case series in the literature, involving twelve patients, and that study addressed a musculoskeletal condition rather than gut healing. A 2026 review confirmed no randomized controlled trials exist for BPC-157 in humans for any indication. The claims that it repairs the gut lining and reduces bloating rest almost entirely on animal studies and community-reported experience.

That community-reported experience is extensive and consistent, which is precisely why it belongs on this list. Across Reddit communities focused on IBS, chronic bloating, and gut health, a clear pattern emerges: users describe meaningful reductions in bloating and stomach distention, often within a few weeks of starting a gut-focused protocol. One frequently cited account describes a person with four years of severe bloating and abdominal pain reporting roughly 80 to 90 percent improvement within ten days of beginning injectable BPC-157. Another describes three months of consistent use resolving persistent GI symptoms that had not responded to other interventions. These are self-reported, uncontrolled observations rather than clinical evidence, but they represent a genuine recurring signal across many independent voices.

BPC-157 is most commonly used as a subcutaneous injection, though some community protocols use an oral form. It is available through peptide therapy clinics and compounding pharmacies, as well as through research chemical channels, though the FDA issued warning letters in early 2026 to firms selling it through that route for human use. Injection site reactions are the most commonly reported side effect under clinic supervision, and short-term tolerability appears reasonable in that context. Long-term effects are not known.

2. KPV: For Direct Gut Inflammation

KPV is a tripeptide composed of three amino acids: lysine, proline, and valine. It is derived from alpha-melanocyte-stimulating hormone, specifically the last three amino acids in that hormone's chain. Like BPC-157, it is a research compound with no FDA approval, but it has developed a consistent following in integrative medicine and gut-healing circles, largely because of how it works alongside BPC-157.

Where BPC-157 focuses on tissue repair and mucosal regeneration, KPV targets inflammation at the intestinal cell level. It acts on inflammatory pathways inside the epithelial cells lining the gut, helping to quiet the immune response that drives much of the irritation underlying chronic bloating. It also appears to support barrier integrity by preserving the tight junctions between gut cells, the protein-based seals that keep the gut wall closed and prevent the kind of intestinal hyperpermeability, commonly called leaky gut, that contributes to chronic symptoms.

The evidence for KPV is preclinical only. Studies conducted in animal models have demonstrated anti-inflammatory effects on gut tissue, but no human clinical trial data has been published for this compound as of 2026. The mechanistic rationale is well-grounded, its molecular origin from a naturally occurring hormone gives practitioners a reasonable theoretical basis for using it, and the animal data supports its described mechanism. The human evidence simply does not exist yet.

In practice, KPV is almost never used alone for bloating. It is most commonly combined with BPC-157, with the pairing targeting both tissue repair and inflammation at the same time. Integrative medicine practitioners who use this combination report synergistic reductions in gut irritation across their patient populations, and community protocols consistently describe meaningful symptom reduction within a few weeks of starting the combination. The pairing has become established enough in practice that it is sometimes marketed under a combined name, even without formal trial data to anchor it.

KPV shares BPC-157's regulatory profile: available through peptide therapy clinics and compounding pharmacies, research compound status outside those channels, and no FDA approval for any indication. Safety data is limited, and short-term supervised use has not raised significant concerns in clinical observation.

3. Collagen Peptides: The Strongest Direct Human Evidence

Collagen peptides occupy an unusual position on this list. They are not exotic, they require no prescription, and they are sold in every health food store. And yet they carry the strongest direct human clinical evidence of any compound here for actually reducing bloating in people.

A registered clinical trial tested hydrolyzed collagen peptides taken daily over eight weeks in fourteen participants. The results were notable for a compound this widely available: thirteen of the fourteen participants experienced reduced bloating, a rate of 93 percent, and average bloating scores dropped by 31 percent over the study period. That is a small trial, and replication at larger scale would be needed before drawing firm conclusions, but it is a real study with a real measured endpoint and a real control period, which places it ahead of most other options in this space on the strength of human evidence alone.

The mechanism fits the symptom. Collagen peptides are rich in glycine and proline, two amino acids that support mucin production. Mucin is the gel-like layer coating the inside of the gut lining, acting as a physical buffer between gut contents and the epithelial cells underneath. When mucin production is adequate, that protective layer stays intact. When it is compromised, the lining becomes more vulnerable to irritation, inflammation, and permeability. Collagen peptides also support broader mucosal healing by supplying these amino acids in an easily absorbed form.

One honest nuance: some people report that collagen peptides cause bloating rather than reducing it, particularly at high doses or when taken on an empty stomach. The likely mechanism is gut bacteria fermenting glycine and hydroxyproline as byproducts, producing gas in the process. The lesson from the clinical data and from community experience combined is that dose and timing matter. Starting at a lower intake taken with food reduces this effect for most people, and the clinical trial that showed a 93 percent reduction rate used a consistent daily protocol with meals.

Collagen peptides are available as a dietary supplement without a prescription, hold a generally recognized as safe designation as a food ingredient, and have a well-established safety profile accumulated over many years of supplement use.

4. Tributyrin: For Gut Barrier Support from the Inside Out

Tributyrin deserves a brief note on classification. It is not a peptide in the traditional sense: it does not consist of amino acid chains. It is a triglyceride, a fat molecule, that the body hydrolyzes in the small intestine to release butyrate, a short-chain fatty acid. It earns a place on this list because it addresses two of the same root causes of chronic bloating that the peptides above target, gut inflammation and intestinal permeability, through a distinct and complementary mechanism, and because it appears consistently in gut health community discussions alongside the peptide compounds.

Butyrate is the primary fuel source for colonocytes, the cells lining the colon. Think of it as the fuel that keeps the colon's engine running: without adequate butyrate, colonocytes underperform, the gut barrier weakens, and inflammation builds. Tributyrin delivers butyrate more efficiently to the colon than direct butyric acid supplementation because the triglyceride form survives passage through the upper GI tract and releases where it is most needed. It also inhibits NF-kB, the same inflammatory signaling switch that BPC-157 acts on, reducing pro-inflammatory cytokine production. And it supports tight junction integrity, reinforcing the physical seals between gut cells that prevent unwanted particles from crossing into circulation and triggering the systemic inflammation that underlies much chronic bloating.

The scientific foundation for butyrate is more established than the literature for most gut-healing peptides. Butyrate and its precursors have been studied across multiple published investigations in IBD, IBS, and gut barrier function. The tributyrin form specifically has been evaluated for its superior delivery compared to direct butyric acid. This is not the same as a clinical trial showing tributyrin reduces bloating in humans as a primary endpoint, because that trial has not been conducted. The support is mechanistic and built from adjacent science: the underlying biology is well grounded, and the application to bloating follows from it logically.

Tributyrin is available as an oral dietary supplement without a prescription, making it among the most accessible options on this list. Some people experience mild and temporary GI adjustment effects, including initial gas, as the microbiome adapts to the changed fuel supply. These effects tend to resolve within the first few weeks of consistent use.

5. Larazotide: For Leaky Gut-Driven Bloating

Larazotide, also referred to as larazotide acetate, is a synthetic octapeptide, a chain of eight amino acids, designed around a highly specific mechanism: blocking the protein that opens gaps in the gut barrier. It is an investigational drug that has moved further through formal clinical evaluation than most compounds on this list, though it has not received FDA approval for general use.

The mechanism is precise in a way that sets larazotide apart from most gut compounds. Tight junctions are the protein-based seals between adjacent gut epithelial cells. Zonulin is a protein the body produces that loosens those seals, creating gaps that allow bacterial fragments, undigested food particles, and inflammatory triggers to cross from the gut into the bloodstream. Larazotide works as a zonulin antagonist, blocking zonulin's ability to open those junctions and helping restore the sealed barrier. For people whose bloating is driven primarily by this kind of permeability, the mechanistic case is among the most direct in this space.

Human trials for larazotide have been completed, studying its effects on gut lining integrity and tight junction function in people. The trial was not designed with bloating as its primary outcome measure, so there is no statistically powered result showing it reduces bloating specifically. What exists is human trial data demonstrating the compound can act on the relevant mechanism in people, which places it in a different category from the entirely preclinical or purely community-reported evidence behind most other entries.

Larazotide is available through peptide therapy clinics and some compounding pharmacies. It is not the first compound most practitioners reach for in general bloating cases. Where it makes the most mechanistic sense is in the more specific presentations: autoimmune gut conditions, celiac disease, Hashimoto's thyroiditis, and any case where the primary driver of gut symptoms is confirmed or strongly suspected intestinal hyperpermeability. For those presentations, the targeted mechanism and the available human data make it a compound worth understanding.

6. TB-500: For Gut Tissue Repair Alongside BPC-157

TB-500 is a synthetic version of a portion of thymosin beta-4, a naturally occurring protein found throughout the body with a well-documented role in tissue repair. It is a research compound with no FDA approval, and the evidence base for its use in gut health and bloating is thinner and less specific than the other entries on this list. It appears here because it shows up consistently in integrative medicine protocols for gut healing and is actively discussed in community circles alongside BPC-157 and KPV.

Its mechanism relevant to bloating centers on actin remodeling. Actin is a structural protein that forms much of the internal scaffolding of cells. When TB-500 binds to actin monomers, it influences how cells move toward areas of damage and how quickly tissue architecture is restored after injury. It promotes angiogenesis through pathways that overlap with BPC-157, supports cell migration into damaged tissue, and reduces inflammation via NF-kB inhibition, the same pathway that butyrate and BPC-157 act on. In integrative medicine settings, some practitioners pair it with BPC-157 for broader mucosal repair, reasoning that the two compounds address overlapping but not identical aspects of gut tissue healing.

No controlled trial has evaluated TB-500 for gut symptoms or bloating. Its use in this context is an extension of its tissue repair properties into the gut setting, based on mechanistic reasoning and practitioner observation rather than published gut-specific data. Community discussion of TB-500 for bloating exists but is less consistent and less detailed than the conversation around BPC-157, and it is typically framed as a supporting addition rather than a stand-alone compound for this goal.

It is available through peptide therapy clinics and research compound channels, with the same regulatory caveats that apply to BPC-157 and KPV. Most people who use it for gut health do so under practitioner supervision, given the limited independent data in this specific application.

How These Peptides Compare

Frequently Asked Questions

Are these compounds legal to use for bloating?

The answer varies by compound and by how it is obtained. Collagen peptides and tributyrin are dietary supplements available without a prescription and carry no significant legal concern for personal use. BPC-157, KPV, and TB-500 occupy a grey area: classified as research compounds, and the FDA issued warning letters in 2026 to firms selling them as research-use-only products when the actual intent was human use, treating them as unapproved new drugs. Larazotide is an investigational compound available through clinics. Accessing injectable peptides through a licensed compounding pharmacy under physician supervision is a materially different situation from purchasing grey-market research chemicals, and the legal and safety picture differs accordingly.

How long before these compounds show any effect on bloating?

It depends on which compound and on the underlying cause of the bloating. Users who report results from injectable BPC-157 often describe noticing change within the first two to three weeks, with some accounts describing improvement beginning within ten days. The BPC-157 and KPV combination protocol has a commonly reported window of two to four weeks to meaningful symptom reduction. Collagen peptides showed measurable improvement across an eight-week study period in the clinical trial that evaluated them for bloating. Tributyrin tends to work more gradually as the microbiome adjusts, on a timeline measured in weeks to months. None of these are guarantees, and results vary based on the root cause being addressed.

Do any peptides cause bloating rather than helping it?

Yes, and this is worth knowing before choosing a compound. GLP-1 receptor agonists like semaglutide and tirzepatide, which are FDA-approved for diabetes and weight loss, commonly cause bloating as a side effect through delayed gastric emptying: these compounds slow the rate at which food moves from the stomach into the intestine, allowing gas to accumulate. Some people also report temporary bloating when starting collagen peptides at higher doses, particularly on an empty stomach, likely from gut bacteria fermenting the amino acids. Starting at a lower intake taken with food reduces this effect for most people.

Does identifying the root cause of bloating matter for compound selection?

It matters considerably. BPC-157 and KPV are most often discussed for general gut inflammation, IBS, and mucosal damage. Larazotide has the most mechanistically targeted rationale for bloating driven by intestinal hyperpermeability and autoimmune gut conditions. Tributyrin and collagen peptides address gut barrier integrity and microbiome support more broadly. Compounds that reduce gut inflammation will not resolve bloating caused primarily by SIBO, slow motility, or food intolerance, because those involve different mechanisms. Working with a practitioner to understand what is actually driving the symptoms leads to better compound selection than choosing from a general list alone.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for bloating in one place.